In summary, GLP-1 RAs represent a promising pharmacological approach for obese patients with OSA, offering both direct and indirect mechanisms for symptom improvement, though further large-scale, long-term studies are warranted to optimize their use and clarify their role in OSA management (101, 102, 108). This evidence concerns the gene GCG and obstructive sleep apnea syndrome.